Today, the Cystic Fibrosis Foundation announced that it will invest up to $8.4 million in SpliSense's Series B funding round to develop an antisense oligonucleotide therapy for people with cystic fibrosis who have splicing mutations and potentially other rare mutations.
Site Search
Showing 61 - 70 of 256 results
News
|
Nov. 15, 2010
|
2 min read
News
|
Jan. 27, 2011
|
2 min read
News
|
Jan. 19, 2010
|
2 min read
News
|
May 17, 2010
|
3 min read
News
|
July 22, 2010
|
2 min read
News
|
Oct. 8, 2010
|
2 min read
News
|
May 13, 2021
|
4 min read
The Cystic Fibrosis Foundation announced the recipients of its sixth annual Impact Grants.
News
|
July 26, 2021
|
5 min read
Marissa Benchea and Jeremy and Rachel Olimb to lead the Foundation’s volunteer advocacy base into a new chapter of CF
News
|
March 31, 2022
|
5 min read
The Cystic Fibrosis Foundation awarded up to $4.7 million to EnBiotix Inc. to study the potential use of inhaled colistin as an additional option to treat Pseudomonas infections in people with cystic fibrosis who are not responding to current treatments.
News
|
Jan. 4, 2022
|
2 min read